{"organizations": [], "uuid": "9f224c94d542f161f876cd2128c4f5a0e7e45f0e", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/2", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/05/08/globe-newswire-altimmune-to-announce-first-quarter-2018-financial-results-on-may-16.html", "country": "US", "domain_rank": 767, "title": "Altimmune to Announce First Quarter 2018 Financial Results on May 16", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.001, "site_type": "news", "published": "2018-05-08T16:00:00.000+03:00", "replies_count": 0, "uuid": "9f224c94d542f161f876cd2128c4f5a0e7e45f0e"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/05/08/globe-newswire-altimmune-to-announce-first-quarter-2018-financial-results-on-may-16.html", "ord_in_thread": 0, "title": "Altimmune to Announce First Quarter 2018 Financial Results on May 16", "locations": [], "entities": {"persons": [], "locations": [{"name": "md.", "sentiment": "none"}, {"name": "gaithersburg", "sentiment": "none"}, {"name": "altimmune", "sentiment": "none"}, {"name": "united states", "sentiment": "none"}], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "GAITHERSBURG, Md., May 08, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced that it will announce financial results for the first quarter ended March 31, 2018 before the market open and host a conference call on Wednesday, May 16.\nConference Call Details\nDate: Wednesday, May 16\nTime: 8:30am Eastern Time\nDomestic: 888-394-8218\nInternational: 323-701-0225\nConference ID: 1336227\nWebcast: http://public.viavid.com/index.php?id=129546\nReplays, Available through May 30th:\nDomestic: 844-512-2921\nInternational: 412-317-6671\nReplay PIN: 1336227\nAbout Altimmune\nAltimmune is a clinical-stage immunotherapeutics company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease including NasoVAX, a Phase 2 seasonal influenza vaccine candidate, and HepTcell, a Phase 1 immunotherapeutic candidate for the potential cure of chronic hepatitis B. The company also has two United States government funded, next-generation anthrax vaccine candidates that are intended to improve protection and safety while having favorable dosage and storage requirements compared to other anthrax vaccines.\nContacts:\nBill Enright\nPresident and CEO\nPhone: 240-654-1450\nenright@altimmune.com\nAshley Robinson\nLifeSci Advisors, LLC\n617-535-7742\narr@lifesciadvisors.com\nSource:Altimmune, Inc.", "external_links": ["http://public.viavid.com/index.php?id=129546", "https://www.globenewswire.com/Tracker?data=GW8uKCfaCJ0_sGI39OXZS3BqqnmivBsF0mzO8foVzVbIusboN-bHcFVc8dglC-iL9roPtI_hguBFiV3tuw1w58drXYbnNKn5MVjsMnLuUqEKlJ-_vVsO5hpgiOf-tvzDL1fMFDovqD9qFUnJ6DnlDg==", "https://www.globenewswire.com/NewsRoom/AttachmentNg/2592324d-a5f2-47e7-8acb-a53f8e235e88"], "published": "2018-05-08T16:00:00.000+03:00", "crawled": "2018-05-08T16:49:19.016+03:00", "highlightTitle": ""}